MarketCap
Facebook
X
Telegram
Apellis Pharmaceuticals Current Ratio | APLS
Annual Current Ratio Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.52 | 1.35 | 1.33 | 1.29 | 1.29 | 1.27 | 5.67 | 11.9 | 27.8 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.8 | 1.27 | 5.93 |
Quarterly Current Ratio Apellis Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.62 | 1.61 | 1.24 | 1.26 | 1.35 | 1.36 | 1.41 | 1.47 | 1.33 | 1.4 | 1.61 | 1.73 | 1.29 | 1.54 | 1.5 | 1.68 | 1.29 | 0.9 | 0.83 | 1.07 | 1.27 | 1.27 | 1.27 | 1.27 | 1.1 | 1.1 | 1.1 | 1.1 | 4.78 | 4.78 | 4.78 | 4.78 | 5.49 | 5.49 | 5.49 | 5.49 | 7.54 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.54 | 0.83 | 2.31 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
0.771 | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
6.18 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
2.92 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
36.5 | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
1.59 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
0.393 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
5.81 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
4.77 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
4.21 | $ 4.0 | -7.62 % | $ 620 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.19 | $ 156.5 | -2.85 % | $ 20.5 B | USA |
 |
Amgen
AMGN
|
1.44 | $ 462.71 | -3.3 % | $ 249 B | USA |
 |
Theratechnologies
THTX
|
0.679 | - | - | $ 83.9 M | Canada |
 |
Iovance Biotherapeutics
IOVA
|
4.26 | $ 7.72 | -11.26 % | $ 2.76 M | USA |
 |
Biogen
BIIB
|
2.63 | $ 243.85 | -4.17 % | $ 35.7 B | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
7.5 | $ 4.03 | 6.9 % | $ 652 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
0.26 | $ 3.01 | -4.14 % | $ 109 M | USA |
 |
Mustang Bio
MBIO
|
2.18 | $ 0.39 | -5.63 % | $ 1.91 M | USA |
 |
MannKind Corporation
MNKD
|
0.939 | $ 3.77 | -4.07 % | $ 1.15 B | USA |
 |
InflaRx N.V.
IFRX
|
4.04 | $ 1.36 | -8.11 % | $ 91.5 M |  Germany |
 |
Immutep Limited
IMMP
|
11.8 | $ 2.7 | -8.47 % | $ 3.93 B |  Australia |
 |
Insmed Incorporated
INSM
|
1.48 | $ 108.79 | -1.1 % | $ 21.7 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
6.05 | - | -3.76 % | $ 3.47 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
4.47 | $ 227.25 | -3.16 % | $ 13.9 B |  Irlanda |
 |
BioLineRx Ltd.
BLRX
|
2.33 | $ 1.77 | -4.95 % | $ 4.36 B |  Israel |
 |
Bristol-Myers Squibb Company
BMY
|
1.26 | $ 63.15 | -1.64 % | $ 128 B | USA |
 |
Johnson & Johnson
JNJ
|
1.69 | $ 272.47 | -1.4 % | $ 656 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
2.19 | - | 3.16 % | $ 1.9 M | USA |
 |
PainReform Ltd.
PRFX
|
4.43 | $ 0.76 | -1.27 % | $ 492 K | Israel |
 |
Kala Pharmaceuticals
KALA
|
3.81 | $ 0.15 | -13.14 % | $ 1.22 M | USA |
 |
Prothena Corporation plc
PRTA
|
7.05 | $ 7.9 | -5.84 % | $ 425 M | USA |
 |
TCR2 Therapeutics
TCRR
|
3.09 | - | - | $ 58.1 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
3.16 | $ 14.53 | -1.63 % | $ 12.1 B |  India |
 |
Keros Therapeutics
KROS
|
9.69 | $ 9.42 | -13.02 % | $ 351 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
8.39 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
0.422 | $ 7.13 | -11.76 % | $ 109 M | Australia |
 |
TFF Pharmaceuticals
TFFP
|
4.89 | - | -60.05 % | $ 125 K | USA |
 |
Sana Biotechnology
SANA
|
1.63 | $ 2.32 | -9.38 % | $ 588 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
1.63 | $ 0.98 | -4.85 % | $ 226 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
2.87 | $ 298.8 | -5.48 % | $ 5.78 B | USA |
 |
Longeveron
LGVN
|
2.24 | $ 1.76 | -1.12 % | $ 30.9 B | USA |
 |
Eli Lilly and Company
LLY
|
1.16 | $ 1 366.97 | -3.62 % | $ 1.23 T | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.05 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
1.77 | - | - | $ 521 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.29 | $ 4.01 | -5.2 % | $ 48.9 M | Israel |
 |
Axcella Health
AXLA
|
1.28 | - | -16.42 % | $ 249 M | USA |
 |
Compugen Ltd.
CGEN
|
7.46 | $ 1.94 | -4.68 % | $ 181 M | Israel |